Internal Medicine, Endocrinology, Diabetes, & Metabolism · San Francisco, CA
NPI
1134210362
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
3
Medicare group memberships
Hospitals
5
Hospital affiliations
350 Parnassus Ave, Suite 707
San Francisco, CA, 94117
Phone (415) 681-7707
Groups this clinician bills Medicare through
Medicare paid, 2024
$299K
10,330 services
Medicare patients, 2024
824
Average age 76
Drug cost, 2024
$2.5M
6,330 prescriptions
Company payments, 2025
$2,097
From 23 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Eric C Buxton was code J0897 (injection, denosumab, 1 mg), 5,340 times for 52 patients. In total Eric C Buxton billed 10,330 services in 11 codes, and Medicare paid $299K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-07-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 5,340 | 52 | $19.03 | $102K |
| 99214 Office E&M - Established | Office | 1,115 | 687 | $105.47 | $118K |
| 99215 Office E&M - Established | Office | 224 | 155 | $153.08 | $34K |
| 96372 Injection Administration | Office | 133 | 58 | $12.05 | $1,602 |
| 99213 Office E&M - Established | Office | 82 | 80 | $69.04 | $5,662 |
| 99204 Office E&M - New | Office | 49 | 49 | $141.39 | $6,928 |
| 99205 Office E&M - New | Office | 21 | 21 | $184.90 | $3,883 |
By year: 2022 $207K for 3,777 services; 2023 $225K for 5,084 services; 2024 $299K for 10,330 services.
Medicare prescription drug claims, 2024
In 2024, the drug Eric C Buxton prescribed most often to Medicare patients was Synthroid (Levothyroxine Sodium), with 863 prescriptions and refills. In total Eric C Buxton wrote 6,330 Medicare prescriptions that cost $2.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Synthroid Levothyroxine Sodium | 863 | 2,211 | 209 | $92K |
| Levothyroxine Sodium Generic | 655 | 1,759 | 173 | $13K |
| Mounjaro Tirzepatide | 410 | 567 | 62 | $590K |
| Metformin Hcl Er Metformin Hcl | 374 | 948 | 110 | $4,218 |
| Liothyronine Sodium Generic | 359 | 934 | 100 | $14K |
| Metformin Hcl Generic | 218 | 556 | 61 | $2,728 |
| Alendronate Sodium Generic | 201 | 551 | 68 | $2,366 |
| Ozempic Semaglutide | 179 | 259 | 32 | $242K |
| Trulicity Dulaglutide | 162 | 223 | 35 | $220K |
| Jardiance Empagliflozin | 150 | 357 | 37 | $206K |
| Atorvastatin Calcium Generic | 128 | 365 | 36 | $1,571 |
| Tirosint Levothyroxine Sodium | 116 | 247 | 21 | $33K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 109 | 281 | 34 | $19K |
| Testosterone Generic | 90 | 181 | 23 | $19K |
| Rybelsus Semaglutide | 88 | 170 | 22 | $155K |
Brand drugs: 3,051 claims; generic drugs: 2,998 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Eric C Buxton $2,097 ($2,097 in general payments such as food, travel and fees) from 23 companies. The largest payer was Antares Pharma, Inc. with $326.
| Company | Payments | Amount |
|---|---|---|
| Antares Pharma, Inc. | 27 | $326 |
| Lilly USA, LLC LLY | 11 | $271 |
| Amgen Inc. AMGN | 13 | $250 |
| Novo Nordisk Inc NVO | 12 | $220 |
| Abbvie Inc. ABBV | 10 | $166 |
| Madrigal Pharmaceuticals MDGL | 6 | $162 |
| Abbott Laboratories ABT | 6 | $113 |
| Ascendis Pharma Endocrinology Inc ASND | 3 | $85.34 |
| Sanofi-Aventis U.S. LLC SNY | 3 | $74.12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $52.48 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.